{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hc:libtayo:1 retrieved successfully",
    "request_url": "https://api.moalmanac.org/indications?indication_id=ind%3Ahc%3Alibtayo%3A1",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.001645,
    "timestamp_received": "2026-11-09T16:12:34.212436Z",
    "timestamp_returned": "2026-11-09T16:12:34.214081Z",
    "trace_id": "486704ec-89cb-4a95-b9b7-de5883180094"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-10-08"
  },
  "data": [
    {
      "id": "ind:hc:libtayo:1",
      "type": "Indication",
      "description": "LIBTAYO (cemiplimab for injection) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with NSCLC whose tumors have no EGFR, ALK or ROS1 aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.",
      "contributions": [],
      "reportedIn": [
        {
          "id": "doc:hc:libtayo",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Libtayo (cemiplimab) [product monograph]. HC.",
          "title": null,
          "aliases": [],
          "description": "Regeneron Canada Company. Libtayo (cemiplimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078455.PDF. Revised January 2025. Accessed June 2025.",
          "urls": [
            "https://pdf.hres.ca/dpd_pm/00078455.PDF",
            "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97728"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:hc",
                "type": "Agent",
                "agentType": "organization",
                "name": "Health Canada",
                "description": "Regulatory agency that approves drugs for sale and use in Canada."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Regeneron Canada Company",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Libtayo",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "cemiplimab",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2019-04-10",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "publication_date",
              "value": "2025-01-30",
              "description": "The publication date for the document."
            },
            {
              "name": "regulatory_identifier",
              "value": null,
              "description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        },
        {
          "name": "statement description",
          "value": "Health Canada approved cemiplimab in cominbation with platinum-based chemotherapy for the first-line treatment of adult patients with NSCLC whose tumors have no EGFR, ALK or ROS1 aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.",
          "description": "The description text for all Statements derived from this Indication."
        }
      ]
    }
  ]
}